These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 9140397)

  • 21. Renal cancer genetics: von Hippel Lindau and other syndromes.
    Fleming S
    Int J Dev Biol; 1999; 43(5):469-71. PubMed ID: 10535326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene structure of the human MET proto-oncogene.
    Duh FM; Scherer SW; Tsui LC; Lerman MI; Zbar B; Schmidt L
    Oncogene; 1997 Sep; 15(13):1583-6. PubMed ID: 9380410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Missense mutation of the MET gene detected in human glioma.
    Moon YW; Weil RJ; Pack SD; Park WS; Pak E; Pham T; Karkera JD; Kim HK; Vortmeyer AO; Fuller BG; Zhuang Z
    Mod Pathol; 2000 Sep; 13(9):973-7. PubMed ID: 11007037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological significance of c-met over expression in papillary renal cell carcinoma.
    Sweeney P; El-Naggar AK; Lin SH; Pisters LL
    J Urol; 2002 Jul; 168(1):51-5. PubMed ID: 12050491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.
    Lorenzato A; Olivero M; Patanè S; Rosso E; Oliaro A; Comoglio PM; Di Renzo MF
    Cancer Res; 2002 Dec; 62(23):7025-30. PubMed ID: 12460923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mechanism of carcinogenesis by germline mutation of protooncogene in hereditary tumors].
    Miyaki M
    Nihon Rinsho; 2000 Jun; 58(6):1225-30. PubMed ID: 10879045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma.
    Wadt KA; Gerdes AM; Hansen TV; Toft BG; Friis-Hansen L; Andersen MK
    Fam Cancer; 2012 Sep; 11(3):535-7. PubMed ID: 22717761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
    Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
    J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.
    Olivero M; Valente G; Bardelli A; Longati P; Ferrero N; Cracco C; Terrone C; Rocca-Rossetti S; Comoglio PM; Di Renzo MF
    Int J Cancer; 1999 Aug; 82(5):640-3. PubMed ID: 10417759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
    Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hereditary papillary renal carcinoma type I.
    Dharmawardana PG; Giubellino A; Bottaro DP
    Curr Mol Med; 2004 Dec; 4(8):855-68. PubMed ID: 15579033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The genetic basis of cancer of the kidney.
    Linehan WM; Walther MM; Zbar B
    J Urol; 2003 Dec; 170(6 Pt 1):2163-72. PubMed ID: 14634372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma.
    Gardie B; Remenieras A; Kattygnarath D; Bombled J; Lefèvre S; Perrier-Trudova V; Rustin P; Barrois M; Slama A; Avril MF; Bessis D; Caron O; Caux F; Collignon P; Coupier I; Cremin C; Dollfus H; Dugast C; Escudier B; Faivre L; Field M; Gilbert-Dussardier B; Janin N; Leport Y; Leroux D; Lipsker D; Malthieu F; McGilliwray B; Maugard C; Méjean A; Mortemousque I; Plessis G; Poppe B; Pruvost-Balland C; Rooker S; Roume J; Soufir N; Steinraths M; Tan MH; Théodore C; Thomas L; Vabres P; Van Glabeke E; Meric JB; Verkarre V; Lenoir G; Joulin V; Deveaux S; Cusin V; Feunteun J; Teh BT; Bressac-de Paillerets B; Richard S;
    J Med Genet; 2011 Apr; 48(4):226-34. PubMed ID: 21398687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Heredity in renal and prostatic neoplasia].
    Prayer Galetti T; D'Arrigo L; De Zorzi L; Patarnello T
    Arch Ital Urol Androl; 1997 Sep; 69(4):241-6. PubMed ID: 9417296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase.
    Ponzetto C; Giordano S; Peverali F; Della Valle G; Abate ML; Vaula G; Comoglio PM
    Oncogene; 1991 Apr; 6(4):553-9. PubMed ID: 1674365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report.
    Ferlicot S; Just PA; Compérat E; Rouleau E; Tissier F; Vaessen C; Richard S
    Diagn Pathol; 2021 Nov; 16(1):107. PubMed ID: 34801057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
    Zhang W; Tan AY; Blumenfeld J; Liu G; Michaeel A; Zhang T; Robinson BD; Salvatore SP; Kapur S; Donahue S; Bobb WO; Rennert H
    Cancer Genet; 2016; 209(1-2):11-20. PubMed ID: 26718059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome.
    Malchoff CD; Sarfarazi M; Tendler B; Forouhar F; Whalen G; Joshi V; Arnold A; Malchoff DM
    J Clin Endocrinol Metab; 2000 May; 85(5):1758-64. PubMed ID: 10843148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
    Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
    Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.